Brief: Algernon Pharmaceuticals Provides Update On Its Phase 1 DMT Stroke Study

Grey Matters Health

07/07/2022 13:04

July 7 (Reuters) - Algernon Pharmaceuticals Inc  AGN.CD :
    * ALGERNON PHARMACEUTICALS PROVIDES UPDATE ON ITS PHASE 1 DMT STROKE STUDY
    * ALGERNON PHARMACEUTICALS INC - CURRENTLY WORKING TO COMPLETE INTRAVENOUS
FORMULATION ("IVF") THAT WILL BE USED IN PHASE 1 DMT STUDY
    * ALGERNON PHARMACEUTICALS INC - PLANNING TO BEGIN PHASE 1 STUDY IN
SEPTEMBER OF
2022
    * ALGERNON PHARMA - RETAINED CENTRE FOR HUMAN DRUG RESEARCH,ITS AFFILIATED
PHARMACY AT LEIDEN UNIVERSITY MEDICAL CENTER IN NETHERLANDS, TO COMPLETE WORK

Source text for Eikon:  ID:nGNX38vtgP 
Further company coverage:  AGN.CD 

 ((Reuters.Briefs@thomsonreuters.com;))